Brisk Walking Program Tested in People With Parkinson's Disease
Tests whether brisk walking improves walking in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease
Key facts
- Where
- Aarhus C, DenmarkSee the site
Where in Denmark
- Aarhus University, Department of Public Health, Sport ScienceAarhus C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT06707402
- Record updated
- 3 July 2025
- Original description
The goal of this clinical trial is to investigate if brisk walking can improve walking function in people with Parkinson's disease and what kind of brisk walking intervention that is most effective. The main questions are:Read full original descriptionShow less
The Effects of 24 Weeks Community-based Brisk Walking on Physical Function, Comorbidities, Cognition, Disease Severity, and Health-related Quality of Life in People With Parkinson's Disease.
The goal of this clinical trial is to investigate if brisk walking can improve walking function in people with Parkinson's disease and what kind of brisk walking intervention that is most effective. The main questions are:
If brisk walking can reduce self-perceived walking difficulty What type of exercise intervention is most effective. Researchers will compare a brisk walking group receiving a personalized walking program with a group receiving an activity tracker and a control group.
Participants will
* be tested at baseline (0 weeks), post the intervention period (24 weeks) and after a follow-up period (48 weeks). * be randomly allocated to one of three groups at baseline. * follow the prescribed intervention they are allocated to.
Inclusion: clinically diagnosed with Parkinson's disease; aged ≥40 years; Hoehn and Yahr stage ≤3; able to independently undertake transportation back and forth from test days and training sessions; expectedly able to complete ≥85% of the training sessions; experience walking difficulties (the generic walking scale (Walk-12G) score ≥8.5).
Exclusion: have another neurological disorder or other disorders that affect gait and balance (e.g., severe arthritis or arthrosis); have dementia (Montreal Cognitive Assessment score \<18); have cardiovascular, respiratory, orthopedic, or metabolic disorders or other medical comorbidities hindering participation in maximal exercise testing; are pregnant; are suffering from alcohol abuse (i.e., exceeding ten units per week, according to the Danish Health Authority recommendation; have a depression; use an activity tracker during exercise; performing high-intensity brisk walking three or more times during a week.